ArticleFrontiers in oncology2026
Transferrin-modified liposomes enhance chemosensitivity in hepatocellular carcinoma by suppressing RDM1-mediated DNA repair.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: RDM1 is linked to poor prognosis in hepatocellular carcinoma (HCC) chemotherapy. We investigated its post-transcriptional regulation and developed a targeted co-delivery strategy to enhance chemosensitivity. Methods: Clinical data were analyzed for RDM1 prognostic value. Post-transcriptional regulation by 5-azacytidine (5-Aza) and synergy with doxorubicin (ADM) were assessed via DNA damage repair and apoptosis assays. A transferrin-modified liposome (AA@Tf-Lip) was constructed for co-delivery, and antitumor efficacy evaluated Results: High RDM1 expression predicted poor HCC survival. 5-Aza downregulated RDM1 by reducing mRNA stability, inhibiting RAD51-mediated homologous recombination repair, and synergistically activating p53/Bax apoptosis with ADM. AA@Tf-Lip enhanced cellular uptake and tumor specificity, achieving higher tumor inhibition and reduced cardiotoxicity versus free drugs. Conclusion: Indirect RDM1 inhibition via post-transcriptional regulation combined with targeted co-delivery effectively enhances HCC chemosensitivity, offering a safe, precise therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.